This morning, positive results from a phase 2a study testing an experimental asthma drug developed by biotech Regeneron (REGN 0.62%) and big pharma company Sanofi (SNY -0.47%) were published in the New England Journal of Medicine. In the following video, health-care analyst Max Macaluso discusses the details of the trial and offers his long-term view on both stocks.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
More positive clinical trial data released today.
Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Sanofi
SNY
$48.29
(-0.47%)
$0.23
Regeneron Pharmaceuticals
REGN
$551.31
(0.62%)
$3.38
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
These Are 2 of the Worst-Performing Stocks in the S&P 500 in 2025
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?
Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income
Is Johnson & Johnson a Good Dividend Stock to Buy Now?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.